Related Experiment Video

Updated: Aug 8, 2026

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
11:31

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System

Published on: August 8, 2012

CC-5013 (Celgene)

Constantine S Mitsiades1, Nicholas Mitsiades

  • 1Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.

Current Opinion in Investigational Drugs (London, England : 2000)
|July 10, 2004
PubMed

Insights

Celgene and the National Cancer Institute are developing CC-5013, a thalidomide derivative, to treat cancers and inflammatory diseases by inhibiting tumor necrosis factor-alpha (TNF-alpha) overproduction.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Tumor necrosis factor-alpha (TNF-alpha) is implicated in various cancers and inflammatory conditions.
  • Thalidomide derivatives offer a potential therapeutic avenue by modulating cytokine production.

Purpose of the Study:

  • To investigate the potential of CC-5013, a novel thalidomide derivative, as a therapeutic agent.
  • To evaluate the efficacy of CC-5013 in treating hematological and solid tumor cancers and inflammatory diseases.

Main Methods:

  • Development of CC-5013, a compound designed to inhibit TNF-alpha overproduction.
  • Preclinical and clinical investigations into the therapeutic effects of CC-5013.

Main Results:

  • CC-5013 demonstrates the ability to inhibit TNF-alpha overproduction.
  • The compound shows promise for the treatment of various cancer types and inflammatory disorders.

Conclusions:

  • CC-5013 represents a promising therapeutic candidate for oncological and inflammatory conditions.
  • Inhibition of TNF-alpha overproduction is a viable strategy for treating these diseases.

More Related Videos

A Spheroid Killing Assay by CAR T Cells08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Cell Lines01:16

Cell Lines

A cell line is a population of cells grown in vitro that can be subcultured over several generations. Normal cells cease to divide after a certain number of cell divisions, a process known as replicative senescence. This number, called the Hayflick limit, was conceptualized by Leonard Hayflick in 1961 when he observed that fetal cells grown in culture could only divide 40-60 times. This limit is due to the shortening of the telomeres during each round of cell division, preventing cell division...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...